New Treatments Update

Last updated on 8 February 2022. 

In this update:

  • Introduction to this new class of treatment
  • PBS Listing & Availability Update
    • Aimovig (erenumab)
    • Emgality (galcanezumab)
    • Ajovy (fremanezumab)
    • Vyepti (eptinezumab-jjmr) [NEW]
  • Timing Expectations
  • Our Response to COVID-19



A new category of treatments has recently been developed to prevent migraine attacks from occurring. These are the Calcitonin Gene-Related Peptides (CGRP) monoclonal antibodies. We have spoken to our community about these new migraine treatments in the past. View this article for more information about the anti-CGRPs or watch a presentation from a headache specialist to learn more about CGRP and other new treatments for migraine.

In Australia, four different manufacturers have applied for Therapeutic Goods Administration (TGA) approval and several have also applied for Pharmaceutical Benefits Scheme (PBS) coverage within the past 2 years. The process can be complicated and time-consuming. Understandably there is some confusion over the availability and access to these treatments.

Below is an update of the current status of each of them:

  • Aimovig (erenumab)
  • Emgality (galcanezumab)
  • Ajovy (fremanezumab)
  • Vyepti (eptinezumab-jjmr) [NEW]



After several failed attempts Novartis withdrew their application for Aimovig coverage on the PBS. The cost for one month treatment and the full dosage of 140ml is $695. Aimovig is only available via a private prescription. Patients order online and have their order shipped to a local pharmacy for pickup.  Novartis stated that they will provide an extra dose free with the first order.


In July 2019, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the inclusion of Emgality (galcanezumab) on the PBS for people with chronic migraine who have unsatisfactorily tried at least three prevention therapies. Emgality was the first medicine of its class to have received a positive recommendation from the PBAC.

With the announcement of the 2021-22 budget, the Federal Government announced that as at 1st June 2021, Emgality would be available on the PBS. Patients must fulfill the following criteria to be eligible for PBS coverage:

  • the patient has chronic migraine
  • three other treatments have failed the patient (for example through a lack of efficacy or intolerable side effects)
  • the script is prescribed by a neurologist

Emgality has an existing program for patients which will continue for those who are not eligible for PBS coverage. The treatment for ineligible patients will cost $263 per month. For those who are able to receive PBS coverage, the monthly cost is $41.30. For concession card holders it’s $6.60.


On 1st August 2021 Ajovy (fremanezumab) was listed on the PBS for chronic migraine patients 15 months after it had received a positive recommendation from the PBAC.

A new prescription from a neurologist will be required to access PBS pricing.

If you aren’t eligible under the PBS criteria, you can still access Ajovy through the Momentum program with a private prescription. The Momentum program allows you to access Ajovy at a reduced price. When you receive your private prescription, your doctor will provide you with the next steps to purchase Ajovy.

Additional information is available from your neurologist. Alternatively, if your neurologist is not aware or if you are not seeing a neurologist then you can contact Teva and request details be directly sent to your doctor. Teva can be reached on Phone: 1800 AU TEVA (1800 28 8382) Email:


Vypeti is another CGRP monoclonal antibody that uses a different method of administration. It is administered intravenously (IV) once every 3 months or four times per year.

Vyepti has been approved in Australia. You can speak to your doctor about accessing Vyepti through their Special Access Scheme (SAS). To achieve optimum efficiency for patients and doctors, Lundbeck Australia has decided to extend the SAS for Vyepti® (eptinezumab) for patients already enrolled in the program in 2021. There will be no new patient enrolments into the SAS Program.

Existing patients can continue on the program.

Lundbeck is monitoring the current situation in the healthcare system and determining the most appropriate time to make Vyepti broadly available for prescribing. A private prescription from a treating neurologist has an estimated cost to the patient of between $1,700 and $1,800 per quarter.

Lundbeck is progressing an application to the PBAC for PBS listing of Vyepti®.


Timing Expectations

With Emgality and Ajovy listed on the PBS it paves the way for others to follow. This has been a long time coming with submissions first called for this new generation preventive treatment over 2 years ago with 1,800 submissions from the migraine community. There have also been several calls for submissions since then. Earlier this year Migraine & Headache Australia’s Carl Cincinnato testified in front of a Parliamentary Enquiry Hearing regarding the approval process of new drugs to share our community’s perspective and the impact of such delays.

The next steps for other treatments which have received a positive recommendation from the PBAC is for price negotiations between the manufacturer and the Department of Health to be agreed. These negotiations can take months or even years. We are hopeful that other CGRPs can follow the roadmap established by Teva (Ajovy) and Eli Lilly (Emgality), leading to faster approvals. This will provide patients with a range of options to discover something that best addresses their migraine disease.

In the meantime we hope this information provides some reassurance that progress is being made. We will continue to represent the patient voice in the need for fair access to proven and safe treatments for migraine.

Discover new treatments & research

Sign up for monthly email updates on the latest treatments, new research, events, news, expert presentations and trials running in Australia. Unsubscribe at any time.

Headache AustralianMigraine & Headache Australia is the only organization in Australia that aims to support the more than 5 million Australians affected by headache and migraine.